Former FDA Commissioner Scott Gottlieb warns of a massive brain drain within the agency’s oncology and hematology divisions, potentially slowing the approval of life-saving treatments for American patients.
The pillars of American pharmaceutical oversight are showing signs of strain as internal staffing shortages and shifting federal rhetoric threaten to disrupt the regulatory environment. During a Sunday appearance on Face the Nation, former FDA Commissioner Scott Gottlieb, who currently serves on the boards of Pfizer and UnitedHealthCare, detailed a concerning exodus of specialized medical reviewers from the Food and Drug Administration.
The staffing crisis is most acute within the agency’s oncology and hematology divisions. According to Gottlieb, the oncology division has seen its ranks of medical reviewers dwindle from approximately 100 down to 50. The hematology department has been even harder hit, dropping from 21 reviewers to just six, while the entire breast cancer review team has reportedly departed. This loss of institutional knowledge and technical expertise creates a significant bottleneck for the approval of new therapies, potentially delaying patient access to innovative treatments while increasing the administrative burden on remaining staff.
Beyond personnel shortages, the agency is navigating a period of leadership uncertainty. Speculation regarding the future of current FDA Commissioner Marty Makary has added a layer of instability to an organization already grappling with a Level 3 emergency response to a hantavirus outbreak aboard the MV Hondius cruise ship. While the CDC has classified this as the least severe activation tier, the logistical challenge of repatriating and monitoring American passengers at facilities like the University of Nebraska Omaha further complicates the federal health agenda.
Policy debates are also intensifying over the management of chronic conditions. Gottlieb raised alarms regarding Secretary Robert F. Kennedy Jr.’s characterization of antidepressants as overprescribed. He cautioned that such rhetoric mirrors previous controversial statements regarding Tylenol use during pregnancy and could deter individuals from seeking medically necessary psychiatric intervention. For a healthcare system grounded in the doctor-patient relationship, such top-down messaging from federal officials risks overriding clinical judgment with political narrative.
Market dynamics continue to shift alongside these regulatory hurdles. While the FDA recently cleared an Investigational New Drug application for Mabwell’s novel antibody 9MW5211 on May 8, 2026, other major reviews are facing delays. Eisai announced that the FDA has extended the review period for its Alzheimer’s treatment, Leqembi, by three months, pushing the PDUFA decision date to August 24, 2026. This delay reflects the increasing pressure on an agency struggling to maintain its review timelines amidst a shrinking workforce.
These developments underscore the fragility of the current regulatory framework. When federal agencies lose the specialized workforce required to vet complex biologics and pharmaceuticals, the cost is ultimately borne by the patient through slower innovation and reduced competition. Preserving the integrity of the FDA requires not only stable leadership but a commitment to maintaining the professional staff who ensure American medicine remains the gold standard for safety and efficacy. Without a robust core of medical reviewers, the sacred doctor-patient relationship is left waiting on a bureaucracy that can no longer keep pace with the speed of scientific discovery.
Susan Carter serves as a Senior Correspondent for Just Right News, where she leads the network’s comprehensive coverage of Health, Medicine, and Public Policy. With a career dedicated to dissecting the complexities of the American healthcare system, Susan brings a principled perspective to the most pressing debates of the day. Her reporting is characterized by a commitment to individual liberty, fiscal responsibility, and a healthy skepticism of government overreach, making her a vital voice for audiences seeking clarity in an increasingly regulated landscape.
Raised in Minneapolis, Minnesota, Susan’s professional outlook is deeply informed by the values of the American heartland. Growing up in the Twin Cities, she witnessed firsthand the importance of community-driven solutions and the resilience of the individual. This Midwestern foundation instilled in her a firm belief that the best answers to public policy challenges often come from local innovation and personal responsibility rather than top-down federal mandates. Her background allows her to translate complex legislative jargon into stories that resonate with families who value common sense and local autonomy.
Now based in Baltimore, Maryland, Susan operates from a unique vantage point at the intersection of medical innovation and urban policy. Living and working in a city renowned for its world-class medical institutions and significant public health challenges, she has a front-row seat to the realities of the modern healthcare landscape. Her proximity to these hubs of research and policy allows her to scrutinize how government intervention affects the quality of care and the freedom of medical professionals. In Baltimore, she sees the tangible results of policy decisions, using the city as a lens through which to examine the broader national health debate and the impact of federal spending on local communities.
As the lead for the acclaimed feature series “The Cost of Care,” Susan dives deep into the economic realities facing patients and providers alike. Her work focuses on the necessity of price transparency, the benefits of market competition, and the preservation of the sacred doctor-patient relationship. She is a staunch advocate for the idea that a well-informed public is the best defense against bureaucratic inefficiency. Through this series, she has exposed the hidden drivers of rising medical expenses, always seeking to empower the individual consumer over the massive institution.
Susan’s reporting on public policy is characterized by a commitment to rigorous inquiry and a focus on constitutional limits. Whether she is analyzing new pharmaceutical regulations, investigating the impact of federal health mandates, or exploring the future of medical technology, her goal remains the same: to provide Just Right News audiences with the facts they need to navigate a complex world. By blending her Midwestern sensibilities with the insights gained from her base in Maryland, Susan Carter has become a trusted authority for those who believe that personal freedom and public health are inextricably linked. Her work continues to challenge the status quo, advocating for a system that respects the taxpayer and prioritizes the patient.